Pramipexole
targets NLRP3 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | MIRAPEX ER | — | 2012-08-31 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | MIRAPEX | — | 2006-11-07 – 2011-05-13 | fda.gov ↗ |
| Approved | EU (EMA) | Sifrol | — | 1997-10-13 | europa.eu ↗ |
| Approved | US (FDA) | MIRAPEX | — | 1997-07-01 | fda.gov ↗ |
Trials 75 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03842709 | May 2019 → Jan 2020 | chronic pain syndrome | University of New Mexico | Completed | No outcome recorded |
| Phase 0 | NCT03430596 | May 2018 → Oct 2021 | extrapyramidal and movement disease | Shanghai Mental Health Center | Completed | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT06457204 | Jul → Aug 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04249544 | Dec 2019 → Jun 2022 | Parkinson disease | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02262546 | May → Oct 2007 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02264132 | Sep → Nov 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00471588 | Aug 2006 → Dec 2007 | obsessive-compulsive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02261103 | Apr → Jul 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02261090 | Jun → Sep 2004 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00666653 | Jul 2003 → May 2007 | Parkinson disease | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04160520 | Oct 2019 → Jan 2023 | urinary system disorder | East Carolina University | Completed | No outcome recorded |
| Phase 1/2 | NCT00600873 | Aug 2007 → Sep 2008 | amyotrophic lateral sclerosis | Bennett, James P., Jr., M.D., Ph.D. | Completed | No outcome recorded |
| Phase 1/2 | NCT00140218 | Aug 2005 → Jan 2007 | amyotrophic lateral sclerosis | Bennett, James P., Jr., M.D., Ph.D. | Completed | No outcome recorded |
| Phase 216 trials | ||||||
| Phase 2 | NCT07022405 | Jan 2026 → Aug 2030 expected | major depressive disorder | Stanford University | Recruiting | No outcome recorded |
| Phase 2 | NCT06611592 | Aug 2024 → Aug 2028 expected | obsessive-compulsive disorder | Clinical Academic Center (2CA-Braga) | Recruiting | No outcome recorded |
| Phase 2 | NCT05401019 | Jun 2022 → Dec 2026 | obsessive-compulsive disorder | Clinical Academic Center (2CA-Braga) | Withdrawn | No outcome recorded |
| Phase 2 | NCT04121091 | Oct 2019 → Mar 2021 | atypical depressive disorder, bipolar depression, dysthymic disorder, major depressive disorder | Region Skane | Completed | No outcome recorded |
| Phase 2 | NCT03683225 | Apr 2019 → Dec 2025 overdue | Parkinson disease | Chase Therapeutics Corporation | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03845387 | Feb 2019 → Feb 2020 | Parkinson disease | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT03642964 | Sep 2018 → Dec 2025 overdue | major depressive disorder | Chase Therapeutics Corporation | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00893841 | Feb 2009 → Jan 2013 | bipolar depression | Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00689052 | Jul → Nov 2008 | fibromyalgia | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 2 | NCT00558467 | Jan 2008 → Jun 2009 | Tourette syndrome | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT02231918 | May 2006 → Jul 2007 | restless legs syndrome | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00152997 | Aug 2004 → Dec 2005 | restless legs syndrome | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00086307 | Jun 2004 → Mar 2010 | major depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 2 | NCT00096720 | Feb 2004 → May 2007 | Parkinson disease | Institute for Neurodegenerative Disorders | Completed | No outcome recorded |
| Phase 2 | NCT00239486 | Oct 2002 → Apr 2004 | restless legs syndrome | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00025792 | Oct 2001 → Nov 2005 | bipolar disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT04759703 | Jan 2022 → May 2024 | opiate dependence, restless legs syndrome, sleep disorder, substance withdrawal syndrome | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 2/3 | NCT01968460 | Dec 2013 → May 2015 | Parkinson disease | Pharma Two B Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT00560508 | Nov 2007 → Nov 2009 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 319 trials | ||||||
| Phase 3 | NCT07664852 | Sep 2026 → Dec 2029 expected | bipolar disorder | Daniel Lindqvist | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05825235 | Apr 2023 → Dec 2025 | atypical depressive disorder, depressive disorder | Region Skane | Completed | No outcome recorded |
| Phase 3 | NCT03765138 | Feb → Aug 2019 | major depressive disorder, post-traumatic stress disorder | Research Foundation for Mental Hygiene, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT03329508 | Jan 2018 → Aug 2021 | Parkinson disease | Pharma Two B Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01191944 | Aug 2010 → Jan 2012 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01106053 | Apr 2010 → Jul 2011 | binge eating disorder | Neuropsychiatric Research Institute, Fargo, North Dakota | Withdrawn | No outcome recorded |
| Phase 3 | NCT00654498 | Apr 2008 → Jun 2009 | restless legs syndrome | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00558025 | Oct 2007 → May 2008 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00479401 | May 2007 → Nov 2008 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00466167 | Apr 2007 → Nov 2008 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00390689 | Oct 2006 → Mar 2008 | restless legs syndrome | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00133198 | Apr 2004 → Feb 2005 | restless legs syndrome | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00152958 | Jan 2004 → Feb 2005 | restless legs syndrome | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00240409 | Jul 2003 → Aug 2004 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00144209 | Feb 2003 → Feb 2005 | restless legs syndrome | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00275457 | Oct 2002 → Apr 2004 | restless legs syndrome | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02172573 | Apr 1999 → Jul 2000 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00274131 | Dec 1998 → Feb 2004 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02177357 | Nov 1998 → Jan 2000 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 422 trials | ||||||
| Phase 4 | NCT06580041 | Nov 2024 → Sep 2029 expected | major depressive disorder | University of California, San Francisco | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT04936126 | Aug 2021 → Jul 2024 | — | All India Institute of Medical Sciences, Bhubaneswar | Unknown | No outcome recorded |
| Phase 4 | NCT03817554 | Jul 2019 → Aug 2020 | restless legs syndrome | Dong Jie | Terminated | No outcome recorded |
| Phase 4 | NCT03521635 | Jul 2018 → Jan 2020 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT02397837 | Oct 2014 → Jul 2018 | bipolar disorder | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02033369 | Feb 2014 → Dec 2016 | major depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT02025608 | Dec 2013 → Dec 2016 | restless legs syndrome | Mauro Manconi | Completed | No outcome recorded |
| Phase 4 | NCT01673724 | Feb 2012 → May 2016 | Parkinson disease | Sandoz | Completed | No outcome recorded |
| Phase 4 | NCT01066897 | Feb 2010 → Feb 2013 | depressive disorder | Stanford University | Terminated | No outcome recorded |
| Phase 4 | NCT00472199 | May 2007 → Jul 2008 | restless legs syndrome | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00402233 | Nov 2006 → Sep 2008 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00375284 | Sep 2006 → Jul 2007 | restless legs syndrome | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00356096 | Jul 2006 → Jun 2007 | depressive disorder, restless legs syndrome | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00349531 | Jul 2006 → May 2007 | restless legs syndrome | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00344994 | May 2006 → Sep 2007 | restless legs syndrome | Augusta University | Completed | No outcome recorded |
| Phase 4 | NCT00321854 | May 2006 → Apr 2009 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00297778 | Mar 2006 → May 2008 | Parkinson disease, depressive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00597896 | Oct 2005 → Apr 2011 | bipolar disorder | Northwell Health | Completed | No outcome recorded |
| Phase 4 | NCT00102856 | Jan 2005 → Jun 2006 | — | University Hospital Muenster | Suspended | No outcome recorded |
| Phase 4 | NCT02231905 | Jan → Nov 2004 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00231959 | Sep 2003 → Sep 2007 | depressive disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02233023 | Jun 1998 → Jun 2000 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03681509 | Sep 2018 → Nov 2019 | — | University of Oxford | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT00596115 | — | amyotrophic lateral sclerosis | Bennett, James P., Jr., M.D., Ph.D. | Temporarily not available | No outcome recorded |
Also used as a comparator or background therapy in 29 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07240675 Comparator | Nov 2025 → Sep 2026 expected | — | Hunan Kelun Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT01651377 Comparator | Oct 2011 → Dec 2012 | cocaine abuse, cocaine dependence | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02260024 Comparator | Oct → Dec 2005 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01074450 Comparator | Feb → Mar 2005 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT01074463 Comparator | Feb → Mar 2005 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06269146 Comparator | May 2024 → Mar 2026 overdue | anxiety, depressive disorder | University of California, San Diego | Recruiting | No outcome recorded |
| Phase 2 | NCT02347059 Comparator | Jan 2015 → Aug 2016 | Parkinson disease | University of Toronto | Unknown | No outcome recorded |
| Phase 2 | NCT00903838 Comparator | Sep 2009 → May 2011 | Parkinson disease | Abbott Products | Terminated | No outcome recorded |
| Phase 2 | NCT00537017 Background | Nov 2007 → Nov 2009 | Parkinson disease, movement disorder, neurodegenerative disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00406029 Background | Nov 2006 → Oct 2008 | Parkinson disease, movement disorder, neurodegenerative disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 311 trials | ||||||
| Phase 3 | NCT05355337 Comparator | Feb 2023 → Jun 2025 | atypical depressive disorder, depressive disorder | Region Skane | Completed | No outcome recorded |
| Phase 3 | NCT01441284 Comparator | Dec 2017 → Dec 2018 | essential tremor | University of Pecs | Withdrawn | No outcome recorded |
| Phase 3 | NCT01320982 Comparator | Mar 2011 → Jun 2012 | schizoaffective disorder, schizophrenia | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT01007864 Comparator | Jan 2010 → Dec 2011 | Parkinson disease | Desitin Arzneimittel GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00991276 Comparator | Dec 2009 → Jun 2011 | restless legs syndrome | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00806026 Comparator | Dec 2008 → May 2011 | restless legs syndrome | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00681863 Comparator | May 2008 → Oct 2009 | Tourette syndrome | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 3 | NCT00601523 Comparator | Jan 2008 → Jun 2010 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00577460 Comparator | Dec 2007 → Jun 2010 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00335166 Comparator | Nov 2006 → Feb 2008 | Parkinson disease | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00275275 Background | Jan 2006 → May 2008 | Parkinson disease | Rajesh Pahwa, MD | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT05003648 Comparator | Apr 2023 → Jul 2025 overdue | adrenoleukodystrophy, restless legs syndrome | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03977441 Background | Jul 2019 → Dec 2020 | Parkinson disease, circadian rhythm sleep disorder, depressive disorder | Second Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 4 | NCT02670161 Comparator | May 2016 → Dec 2026 expected | Parkinson disease, brain neoplasm, cognitive impairment with or without cerebellar ataxia, epilepsy +6 | Endeavor Health | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT01048229 Comparator | Oct 2008 → Mar 2010 | Parkinson disease | Qualissima | Terminated | No outcome recorded |
| Phase 4 | NCT00399477 Background | Oct 2006 → Jul 2007 | Parkinson disease | Teva Neuroscience, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00144300 Comparator | Jan 2005 → Sep 2010 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT01470859 Comparator | Dec 2011 → Aug 2014 | Parkinson disease | Huashan Hospital | Completed | No outcome recorded |
| — | NCT00282152 Background | Mar 2006 → Jan 2012 | Parkinson disease | Vanderbilt University Medical Center | Completed | No outcome recorded |
Evidence & citations 23 cited values
Every value below carries the sentence it was read from. 107 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pramipexole | “The objectives of this trial conducted in early Parkinson's Disease (PD) patients are to determine the efficacy (as measured by the change from baseline to the end of the...” NCT00479401 ↗99“The general aim of this trial is to determine the efficacy (as measured by the change from baseline to the end of the maintenance phase in the total score for Unified...” NCT00466167 ↗ “Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O...” NCT00537017 ↗ “Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the...” NCT00406029 ↗ “A conversion study of Mirapex (pramipexole) to Requip (ropinirole) controlled release (CR) in patients with Parkinson's disease to determine the appropriate conversion ratio...” NCT00275275 ↗ “Study to assess the safety, tolerability and effectiveness of a switching from Domin® (talipexole) tablet to BI Sifrol® (pramipexole) tablet in patients with Parkinson's disease” NCT02231905 ↗ “Different doses (0.125 mg, 0.25 mg, 0.5 mg) of Pramipexole Administered Once Daily Orally in Pediatric Patients” NCT02231918 ↗ “Pramipexole group: Consenting individuals meeting accession criteria will start pramipexole 2.0mg daily dose” NCT03642964 ↗ “Patients received labeled IR regimens of pramipexole (n = 121) or ropinirole (n = 125) for 2 years.” PMID 28078162 ↗ Dec 2016 “Examples of drugs used include carbidopa/levodopa, pramipexole, ropinirole, and selegiline.” NCT00282152 ↗ “control group:Pramipexole+pIacebo experimental group:Pramipexole+Agomelatine” NCT03977441 ↗ “Parkinson's disease (pramipexole, ropinerole, rotigotine)” NCT02670161 ↗ “pramipexole ER, given with aprepitant” NCT03683225 ↗ |
| Known as | BI Sifrol | “Study to assess the safety, tolerability and effectiveness of a switching from Domin® (talipexole) tablet to BI Sifrol® (pramipexole) tablet in patients with Parkinson's disease” NCT02231905 ↗2“The efficacy and safety of long-term treatment with pramipexole (BI Sifrol®) were evaluated in Parkinson disease patients in an open-label non-controlled design.” NCT00274131 ↗ “Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome” NCT00152997 ↗ |
| Known as | Mirapex | “The dose and route of administration of pramipexole will be identical to that previously approved for the treatment of Restless Legs Syndrome and according to manufacturer's...” NCT03842709 ↗9“Preliminary studies suggest that pramipexole (Mirapex), a dopaminergic-agent that is FDA-approved for Parkinson's Disease, may have antidepressant properties in unipolar and...” NCT00025792 ↗ “A conversion study of Mirapex (pramipexole) to Requip (ropinirole) controlled release (CR) in patients with Parkinson's disease to determine the appropriate conversion ratio...” NCT00275275 ↗ “A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS” NCT00375284 ↗ “This study will evaluate the effectiveness of pramipexole (Mirapex) in managing treatment-resistant depression.” NCT00231959 ↗ “fixed doses of 0.25 mg, 0.50 mg and 0.75 mg Pramipexole (Mirapex®) Administered Orally” NCT00133198 ↗ “Pramipexole (Mirapex) tablets are taken orally, with or without food.” NCT06269146 ↗ “Mirapex (pramipexole)” NCT00096720 ↗ “Mirapex (pramipexole)” NCT00344994 ↗ |
| Known as | Mirapexin | “A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol, Mirapexin) 0.125-0.75 mg/Day Per os to Investigate the Long-term...” NCT00472199 ↗2“Trial With 0.125-0.75 mg/Day Pramipexole (Sifrol®, Mirapexin®) Orally for 12 Weeks” NCT00356096 ↗ “Pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/Day Per os” NCT00349531 ↗ |
| Known as | PPX | “The objective of the open-label phase is to assess the safety profile and effect of Pramipexole (PPX) extended-release (ER) in fibromyalgia patients over a 24-week period.” NCT00689052 ↗4“R+ pramipexole (PPX) is a lipophilic cation that concentrates into brain and mitochondria and efficiently scavenges reactive oxygen and nitrogen species (RONS).” PMID 18270879 ↗ Feb 2008 “Subjects were randomized to receive either pramipexole (PPX) or placebo for the initial 5 weeks of the study” NCT00666653 ↗ “pharmacokinetics (PK) of pramipexole (PPX) after administration” NCT02231918 ↗ “dopamine agonist pramipexole (PPX) versus reference treatment” PMID 22101745 ↗ Nov 2011 |
| Known as | PPX ER | “Pramipexole Extended Release (PPX ER)” NCT00479401 ↗ |
| Known as | PPX IR | “Pramipexole Immediate Release (PPX IR)” NCT00479401 ↗ |
| Known as | pramipexol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00806026 ↗ |
| Known as | Pramipexol Extended Release | “Drug: Pramipexol Extended Release” NCT00466167 ↗1“Drug: Pramipexol Extended Release” NCT00479401 ↗ |
| Known as | Pramipexol Immediate Release | “Drug: Pramipexol Immediate Release” NCT00466167 ↗1“Drug: Pramipexol Immediate Release” NCT00479401 ↗ |
| Known as | Pramipexole Dihydrochloride | “Pramipexole Dihydrochloride Tablets 0.25 mg by Barr Laboratories, Inc.” NCT01074450 ↗1“Pramipexole Dihydrochloride 0.25 mg Tablets” NCT01074463 ↗ |
| Known as | pramipexole ER | “The general aim of this trial is to determine the efficacy (as measured by the change from baseline to the end of the maintenance phase in the total score for Unified...” NCT00466167 ↗3“In addition, this study will also compare P2B001 to a marketed drug of pramipexole ER.” NCT03329508 ↗ “pramipexole ER, given with aprepitant” NCT03683225 ↗ “Drug: pramipexole ER” NCT00689052 ↗ |
| Known as | Pramipexole Extended Release | “The objectives of this trial conducted in early Parkinson's Disease (PD) patients are to determine the efficacy (as measured by the change from baseline to the end of the...” NCT00479401 ↗1“A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release (ER)...” NCT00466167 ↗ |
| Known as | pramipexole hydrochloride | “10 volunteers receive pramipexole hydrochloride sustained-release tablets 0.375mg” NCT07240675 ↗ |
| Known as | pramipexole immediate release | “A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release (ER)...” NCT00466167 ↗1“the efficacy of Pramipexole Immediate Release (IR) will be compared to placebo, for assay sensitivity” NCT00479401 ↗ |
| Known as | R(+)PPX | “R(+) pramipexole dihydrochloride monohydrate \[R(+)PPX\], an experimental neuroprotective drug” NCT00596115 ↗ |
| Known as | R+ pramipexole | “R+ pramipexole (PPX) is a lipophilic cation that concentrates into brain and mitochondria and efficiently scavenges reactive oxygen and nitrogen species (RONS).” PMID 18270879 ↗ Feb 2008 |
| Known as | Ropirinole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02347059 ↗ |
| Known as | Sifrol | “A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol, Mirapexin) 0.125-0.75 mg/Day Per os to Investigate the Long-term...” NCT00472199 ↗7“A Randomised, Double-blind, Placebo-controlled Dose Titration Trial With 0.125-0.75 mg Pramipexole (Sifrol®) Orally to Investigate the Safety and Efficacy in Out-patients With...” NCT00275457 ↗ “1 tablet Sifrol® (pramipexole) manufactured in Ingelheim containing 0.088 mg pramipexole taken orally after an overnight fast of at least 10 hours.” NCT06457204 ↗ “Trial With 0.125-0.75 mg/Day Pramipexole (Sifrol®, Mirapexin®) Orally for 12 Weeks” NCT00356096 ↗ “Pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/Day Per os” NCT00349531 ↗ “0.125-0.75 mg Pramipexole (Sifrol®) Orally q.n.” NCT00654498 ↗ “pramipexole (Sifrol) 0.25 mg to 0.75 mg daily” NCT00144209 ↗ “different doses of pramipexole (Sifrol)” NCT00239486 ↗ |
| Known as | SND 919 | “The objective of the study was to evaluate the efficacy and safety of SND 919 (pramipexole) tablets administered in combination with L-dopa in patients with Parkinson's disease...” NCT02172573 ↗ |
| Action | Activate | “The D₂/D₃ receptor agonist pramipexole has clinical efficacy as an antidepressant” PMID 21029512 ↗ Oct 2010 |
| Route | Oral | “Administered Orally” NCT00133198 ↗ |
| Target | NLRP3 | “pramipexole blocks the activation of NLRP3” NCT03842709 ↗ |